Anaveon_dark_blue_logo high res.jpg
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
29 mai 2024 02h00 HE | Anaveon
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
Anaveon_dark_blue_logo high res.jpg
Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting
23 mars 2023 03h00 HE | Anaveon
BASEL, Switzerland, March 23, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Association for...
Anaveon_dark_blue_logo high res.jpg
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma
02 févr. 2023 02h00 HE | Anaveon
BASEL, Switzerland, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient has been dosed in the OMNIA-1 study – a Phase I/II study...
Anaveon_dark_blue_logo high res.jpg
Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022
10 sept. 2022 03h00 HE | Anaveon
- ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity – - A Phase II program of ANV419 has been initiated in...
Anaveon_dark_blue_logo high res.jpg
Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022
08 avr. 2022 13h00 HE | Anaveon
- ANV419 is very well-tolerated and demonstrates exceptional safety with strong pharmacodynamic effects and excellent IL-2Rβγ selectivity - - A Phase II program of ANV419 has been initiated in...
Anaveon_dark_blue_logo high res.jpg
Anaveon to raise CHF 110 million in oversubscribed Series B financing
16 déc. 2021 02h00 HE | Anaveon
- Leading international syndicate led by Forbion and corner-stoned by founding investor Syncona- Confirms depth of support for Anaveon’s approach to developing engineered cytokines in multiple...
Pandion-Logo-RGB-large.png
Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
04 janv. 2021 08h00 HE | Pandion Therapeutics, Inc.
-Phase 1a trial achieved primary objective of safety and tolerability-PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in...
XOMA royalty-2c.png
New XOMA Antibodies Unveiled at The Society for Immunotherapy of Cancer 31st Annual Meeting
08 nov. 2016 09h00 HE | XOMA Ltd.
Preclinical Data from XOMA’s Novel Anti-IL-2 Immuno-oncology Monoclonal Antibodies Program to be Presented at SITCAdvancing Unique Functional Antibody Antagonists Targeting the Parathyroid Hormone...